List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 48 studies with search of: "Ascites"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
Conditions: Ascites;   Liver Cirrhosis
Interventions: Drug: satavaptan (SR121463B);   Drug: placebo
2 Completed Satavaptan Dose-Ranging Study in the Prevention of Ascites
Conditions: Ascites;   Liver Cirrhosis
Intervention: Drug: satavaptan (SR121463B)
3 Terminated Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Conditions: Ascites;   Liver Cirrhosis
Interventions: Drug: satavaptan (SR121463B);   Drug: placebo
4 Terminated Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Conditions: Ascites;   Liver Cirrhosis
Interventions: Drug: satavaptan (SR121463B);   Drug: placebo
5 Recruiting Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Conditions: Ovarian Neoplasms;   Ascites
Intervention: Drug: catumaxomab
6 Recruiting Trial of Sunitinib for Refractory Malignant Ascites
Condition: Ascites
Intervention: Drug: Sunitinib
7 Recruiting Sodium Restriction in the Management of Cirrhotic Ascites
Condition: Ascites
Interventions: Other: Sodium restriction;   Other: Sodium restriction
8 Completed Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
Conditions: Ascites;   Liver Cirrhosis
Intervention: Drug: satavaptan (SR121463B)
9 Completed Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
Conditions: Ascites;   Liver Cirrhosis
Intervention: Drug: satavaptan (SR121463B)
10 Active, not recruiting Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Conditions: Ovarian Neoplasms;   Ascites
Interventions: Drug: aflibercept (AVE0005 / VEGF Trap);   Drug: placebo
11 Completed North American Study for the Treatment of Refractory Ascites (NASTRA)
Conditions: Ascites;   Liver Cirrhosis
Interventions: Procedure: Transjugular intrahepatic portasystemic shunts (TIPS);   Procedure: Total paracentecis (TP)
12 Not yet recruiting Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function
Condition: Cirrhosis With Ascites
Interventions: Drug: hydrocortisone;   Drug: dextrose solution 5%
13 Recruiting CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Conditions: Cancer;   Neoplasms;   Carcinoma;   Malignant Ascites
Interventions: Drug: Catumaxomab;   Drug: Prednisolone
14 Completed Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
Conditions: EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast);   Malignant Ascites
Interventions: Biological: Catumaxomab (Removab);   Procedure: paracentesis
15 Active, not recruiting A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal
Condition: Refractory Ascites
Intervention: Device: AFS System
16 Completed Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
Conditions: Cirrhosis;   Ascites
Interventions: Drug: Spironolactone and furosemide;   Drug: Spironolactone and furosemide
17 Recruiting Prevention of Decompensation in Liver Cirrhosis
Conditions: Alcoholic Liver Cirrhosis;   Ascites
Intervention: Drug: losartan (drug)
18 Suspended Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
Conditions: Cirrhosis;   Ascites
Interventions: Drug: 20% Human Albumin;   Drug: Normal Saline
19 Completed The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
Conditions: Type 2 Hepatorenal Syndrome;   Refractory Ascites
Interventions: Drug: Midodrine, albumin, octreotide LAR;   Drug: midodrine, octreotide, albumin
20 Recruiting Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction
Condition: Tense Ascites in Cirrhosis
Interventions: Drug: albumin 4 gr/L ascites removed;   Drug: albumin 8 gr/L ascites removed

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services